Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 9, 2003, Pages 915-919

  Pham Dang, My Lan ^a   Clement, Robert ^a   Mercier, Isabelle ^a   Calderone, Angelino ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

AT1 receptor antagonists; Hemodynamics; Ovariectomy; Tamoxifen

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENDOMETRIUM ATROPHY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE CONTRACTION; MEAN ARTERIAL PRESSURE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SHAM FEEDING; SPECIES COMPARISON;

EID: 0141839121     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-086     Document Type: Article

References (20)

1. Bjarnason, N.H., Haarbo, J., Byrjalsen, I., Kauffman, R.F., and Christiansen, C. 1997. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation, 96: 1964-1969.
2. Clarke, S.C., Schofield, P.M., Grace, A., Metcalfe, J.C., and Kirschenlohr, H.L. 2001. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation, 103: 1497-1502.
3. Figtree, G.A., Lu, Y.-Q., Webb, C.M., and Collins, P. 1999. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation, 100: 1095-1101.
4. Figtree, G.A., Webb, C.M., and Collins, P. 2000. Tamoxifen acutely relaxes rabbit coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J. Pharmacol. Exp. Ther. 295: 519-523.
5. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., and Vittinghoff, E. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280: 605-613.
6. Kannel, W.B., McGee, D., and Gordon, T. 1976. A general cardiovascular risk profile: the Framingham study. Am. J. Cardiol. 38: 46-51.
7. MacGregor, J.I., and Jordan, V.C. 1998. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50: 152-196.
8. A receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis. Br. J. Pharmacol. 136: 685-692.
9. A-receptor antagonist. Circulation, 96: 1593-1597.
10. 1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodelling post-MI. Br. J. Pharmacol. 138: 1485-1494.
11. Nuedling, S., Kahlert, S., Loebbert, K., Doevendans, P.A., Meyer, R., Vetter, H., and Grohe, C. 1999. 17β-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc. Res. 43: 666-674.
12. Paulus, W.J., Vantrimpont, P.J., and Shah, A.M. 1994. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Circulation, 89: 2070-2078.
13. Ponicke, K., Heinroth-Hoffmann, I., Becker, K., and Brodde, O.E. 1997. Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocytes. Br. J. Pharmacol. 121: 118-124.
14. Prendergast, B.D., Sagach, V.F., and Shah, A.M. 1997. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation, 96: 1320-1329.
15. Reckeloff, J.F. 2001. Gender differences in the regulation of blood pressure. Hypertension, 37: 1199-1208.
16. Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized control trial. J. Am. Med. Assoc. 288: 321-333.
17. Stokes, J., Kannel, W.B., Wolf, P.A., D'Agostino, R.B., and Cupples, L.A. 1989. Blood pressure as a risk for cardiovascular disease: the Framingham study - 30 years of follow-up. Hypertension, 13(Suppl I): I13-I18.
18. Touyz, R.M. 2003 The role of angiotensin II in regulating vascular structure and functional changes in hypertension. Curr. Hypertens. Rep. 5: 135-143.
19. Walsh, B.W., Kuller, L.H., Wild, R.A., Paul, S., Farmer, M., Lawrence, J.B., et al. 1998. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 279: 1445-1451.
20. Wilcox, J.G., Hatch, I.E., Gentzschein, E., Stanczyk, F.Z., and Lobo, R.A. 1997. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil. Steril. 67: 273-277.